Goldman Sachs Initiates Coverage on Natera, Inc. (NTRA)

Natera, Inc. (NASDAQ:NTRA) is one of the 8 Best Genomics Stocks to Buy According to Analysts.

On June 5, Goldman Sachs initiated coverage on Natera, Inc. (NASDAQ:NTRA) with a Neutral rating and a $245 price target, noting the firm’s leadership in the molecular residual disease testing market. Analyst Evie Koslosky pointed to “strong” commercial execution and a tumor-informed approach resulting in higher sensitivity. Goldman is expecting clearer operating leverage as the company continues reinvesting in growth.

On June 4, Natera, Inc. (NASDAQ:NTRA) announced a collaboration with CytoDyn to evaluate circulating tumor DNA dynamics in metastatic colorectal cancer. Under the agreement, Natera said it will examine CLOVER Phase 2 trial samples using its Signatera assay. It will also deliver real-world data insights drawn from a database exceeding 2 million plasma timepoints.

Goldman Sachs Initiates Coverage on Natera, Inc. (NTRA)

Likoper/Shutterstock.com

CytoDyn CEO Jacob Lalezari said the partnership will generate insights into “ctDNA response kinetics and disease progression.” Natera’s Vice President, Biopharma Data & AI Partnering, Matt Love, added that the platform helps partners “better understand disease biology, treatment response, and patient outcomes.”

Natera, Inc. (NASDAQ:NTRA) is a diagnostics company that discovers, develops, and markets genetic testing services. It provides Panorama non-invasive prenatal test, Vistara, horizon carrier screening, spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception, and non-invasive paternity testing.

While we acknowledge the risk and potential of NTRA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than NTRA and that has 10,000% upside potential, check out our report about the cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1